A Search Service for Abbreviation / Long Form

â–  Abbreviation / Long Form : ADA / anti-drug antibodies

[Related PubMed/MEDLINE]
Total Number of Papers: 263
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ADA  (>> Co-occurring Abbreviation)
Long Form:   anti-drug antibodies
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A Model-Based Approach to Quantify the Time-Course of Anti-Drug Antibodies for Therapeutic Proteins. ---
2019 Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. AAV, mAbs
2019 An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. DAS28-CRP, OLE, RA, RP, SAEs, TEAEs
2019 Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. ---
2019 Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. ADA-NEG, TE-POS
2019 Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. AUC, DMARDs, ROC, SpA
2019 Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis: a retrospective observational study. TNF, UC
2019 Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity. CIC, HAEs, Phe, PKU
2019 Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. IFN-beta
10  2019 HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). GAA, iTEM, rhGAA
11  2019 Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab. ELISA, IL, nADA, SPR, UST
12  2019 Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. DT-EIA, EIA
13  2019 Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis. PASI
14  2019 Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. CLB, NAb
15  2019 PF-06881893 (Nivestymâ„¢), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. ANC, AUEC, CD, HVs, PD, PK, US-Neupogen
16  2019 Prediction of natalizumab anti-drug antibodies persistency. MSD, PK
17  2019 Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. ---
18  2019 Use of Ella to facilitate drug quantification and antidrug antibody detection in preclinical studies. ---
19  2018 A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. ACR20, PK, RA
20  2018 A simple and cost-effective assay for measuring anti-drug antibody in human patients treated with Adalimumab. LOD
21  2018 Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1. ---
22  2018 Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. mAbs
23  2018 Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA. HCPs, HSA, OsrHSA
24  2018 Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. CIC, HAE, Ig, PEG, Phe, PKU
25  2018 Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing. Ab, BEAD, BEHD, BEHD, NAb
26  2018 Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies. ---
27  2018 Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. BLI, ECL, EPO, SPR, WHO
28  2018 Construction of Macaque Immune-Libraries. ---
29  2018 Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay. CI-M6PR, ERTs, NAbs
30  2018 Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naive Subjects. ASC, SFU
31  2018 Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. AEs, CAPS, CRP, DSSS, PK, SAA
32  2018 Development of an anti-EPO antibody detection kit based on lab-on-a-chip and bridging antibody technologies. PRCA
33  2018 Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay. ACE, ADAL, HMSA, IFX
34  2018 Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment. CD, IBD, IFX, TL, UC
35  2018 Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. ADL, ETN, INF
36  2018 Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney. ASO
37  2018 Humoral Immune Response After Intravitreal But Not After Subretinal AAV8 in Primates and Patients. NHP, rAAV8, vg
38  2018 IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution. IFX
39  2018 Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. TNF
40  2018 Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy. ---
41  2018 Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. DT-EIA
42  2018 Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan. ---
43  2018 Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection. IC
44  2018 Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study. CSF, ERT, i.c.v, ML, NAb
45  2018 Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. RA
46  2018 Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. CD, ELISA, HMSA, UC
47  2018 Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients. IFN-beta, MS
48  2018 Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFalpha Monoclonal Antibody. MTX, PsA, TP-DI
49  2018 Isolation and Characterization of Novel Phage Displayed scFv Fragment for Human Tumor Necrosis Factor Alpha and Molecular Docking Analysis of Their Interactions. TNF-alpha
50  2018 Low Percentage of Signal Regulatory Protein alpha/beta+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. AUC, DEMs, RA, ROC, SIRP, TNF
51  2018 MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. MAPPs
52  2018 Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. AID, BAFFtg, MTX, TNFi, WT
53  2018 Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact? FD
54  2018 Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. AUC, AUC0-336, GMRs, PK
55  2018 Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. anti-CMV, PK
56  2018 Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. PK, s.c, TMDD
57  2018 Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. TEAEs
58  2018 Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. DLT
59  2018 Population Pharmacokinetics of the TNF-alpha and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials. PsA, RA
60  2018 Preclinical Pharmacokinetics of a Novel anti-c-Met Antibody-Drug Conjugate, SHR-A1403, in Rodents and Non-human Primates. ADC, DAR, IND, PK
61  2018 Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies. ---
62  2018 Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies. ---
63  2018 Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. ACR, INF, RA
64  2018 Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. AEs, IM, LRTIs, RSV
65  2018 Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics. PCs
66  2018 Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial. FPG, LFTs, s.c
67  2018 T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis. IFX
68  2018 The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. ADEs
69  2018 The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature. PsA
70  2018 The Immunogenicity of Biologic Therapies. IC, mAbs
71  2018 The New Test for Monitoring Infliximab Therapy: From Laboratory to Clinical Practice. Free-ADA, Total-ADA
72  2018 Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects. NAb, PK
73  2017 A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay. BEAD, ECL, NAb, PK
74  2017 A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. TEAEs
75  2017 A Proposal to Redefine Clinical Immunogenicity Assessment. TP
76  2017 A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. ACR20, INF, PK, RA
77  2017 A Randomized Phase 1 Study to Assess the Safety and Pharmacokinetics of the Subcutaneously Injected Anti-LIGHT Antibody, SAR252067. AEs
78  2017 A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. ADL, AUCinf, AUClast, ELISA, EU-ADL, NAb, PK, TEAEs, US-ADL
79  2017 A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples. Abs, dAb, ECLIA
80  2017 An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. MM, NAbs, SLAMF7
81  2017 Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development. APCs
82  2017 Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. TDM
83  2017 Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments. ---
84  2017 Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost. ---
85  2017 Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study. ---
86  2017 Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization. BP, DC, hGH, MoDC
87  2017 Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. RIT
88  2017 Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. IBD
89  2017 Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure. ERT, PK
90  2017 Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. ERT
91  2017 Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients. mAbs
92  2017 Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice. mAbs
93  2017 Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context. PK
94  2017 Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. ---
95  2017 Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody. IL-5
96  2017 LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects. PK
97  2017 Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat. PEG
98  2017 Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. csDMARDs, PK, RA, s.c, TCZ
99  2017 Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce. FIX, IgG, ITI
100  2017 Persistency of Neutralizing Anti-Interferon-beta Antibodies in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon-beta Depends on Antibody Titers, IgG Subclasses, and Affinity Maturation. IFN, MS